BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 36313145)

  • 1. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom's macroglobulinemia.
    Izutsu K; Kato H; Sekiguchi N; Fujisaki T; Kawakita T; Obara N; Matsue K; Nishimoto M; Hatayama T; Inagaki M; Fujikawa E
    Int J Hematol; 2024 Apr; ():. PubMed ID: 38597986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of orelabrutinib treatment in three cases of refractory/relapsed autoimmune haemolytic anaemia/Evans syndrome.
    Liu H; Ding K; Zhang W; Xing L; Wang Y; Wang H; Song J; Li L; Fu R
    Br J Haematol; 2024 Mar; 204(3):1082-1085. PubMed ID: 37932927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
    Kaiser LM; Harms M; Sauter D; Rawat VPS; Glitscher M; Hildt E; Tews D; Hunter Z; Münch J; Buske C
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of relapsed idiopathic multicentric Castleman disease-idiopathic plasmacytic lymphadenopathy with orelabrutinib monotherapy: A case report.
    Gao YH; Duan MH; Li J; Zhang L
    Br J Haematol; 2024 Jun; ():. PubMed ID: 38859582
    [No Abstract]   [Full Text] [Related]  

  • 5. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
    Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
    Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to Treat Diffuse Large B-Cell Lymphoma: Oncologic and Cardiovascular Considerations.
    Kambhampati S; Herrera AF; Rhee JW
    JACC CardioOncol; 2023 Jun; 5(3):281-291. PubMed ID: 37397077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.
    Sarosiek S; Castillo JJ
    Drugs; 2024 Jan; 84(1):17-25. PubMed ID: 38055179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Wei R; Wu Y; Jiang S; Zhang A; Zhang L; Liu L; Wang Y; Zhang M; Mei H; Liu F; Xia L; Cui G; Fang J
    Clin Exp Med; 2023 Dec; 23(8):4609-4621. PubMed ID: 37925380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies.
    Song Y; Wu SJ; Shen Z; Zhao D; Chan TSY; Huang H; Qiu L; Li J; Tan TD; Zhu J; Song Y; Huang WH; Zhao W; Liu HSY; Xu W; Chen N; Ma J; Chang CS; Tse EWC
    Exp Hematol Oncol; 2023 Oct; 12(1):92. PubMed ID: 37845755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
    Deng LJ; Zhou KS; Liu LH; Zhang MZ; Li ZM; Ji CY; Xu W; Liu T; Xu B; Wang X; Gao SJ; Zhang HL; Hu Y; Li Y; Cheng Y; Yang HY; Cao JN; Zhu ZM; Hu JD; Zhang W; Jing HM; Ding KY; Zhang XY; Zhao RB; Zhang B; Tian YM; Song YP; Song YQ; Zhu J
    Blood Adv; 2023 Aug; 7(16):4349-4357. PubMed ID: 37078706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS.
    Sun LN; Zhao Y; Qian ZY; Chen XL; Ma H; Guo YJ; Shen H; Wang YQ
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
    Cao XX; Jin J; Fu CC; Yi SH; Zhao WL; Sun ZM; Yang W; Li DJ; Cui GH; Hu JD; Liu T; Song YP; Xu B; Zhu ZM; Xu W; Zhang MZ; Tian YM; Zhang B; Zhao RB; Zhou DB
    EClinicalMedicine; 2022 Oct; 52():101682. PubMed ID: 36313145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
    Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
    Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
    An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
    Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
    Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.